載入...
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
BACKGROUND:Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that along with two nucleoside reverse transcriptase inhibitors is one of several regimens recommended by the United States, United Kingdom and European Union for first-line antiretroviral treatment of peop...
Na minha lista:
Main Authors: | , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
Public Library of Science (PLoS)
2016-01-01
|
叢編: | PLoS ONE |
在線閱讀: | http://europepmc.org/articles/PMC5063380?pdf=render |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|